Cowen and Company’s TherapeuticsMD TXMD Stock Holding History

Cowen and Company’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-262	Closed	-$48K	–	592
2019 Q3	$48K	Buy	+262	New	+$36.9K	0.01%	325

Other funds holding TXMD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cowen and Company's TXMD Position: Q4 2019 in Review

Cowen and Company sold out of TherapeuticsMD (TXMD) in Q4 2019, closing a stake of 262 shares — an estimated $48K sold.

Cowen and Company first reported a position in TXMD in Q3 2019 and held it in 1 quarter. The position peaked at $48K in Q3 2019. 168 funds tracked by Wall St. Rank hold TXMD as of Q4 2019.

Cowen and Company reported no remaining TherapeuticsMD position as of Q4 2019 after selling out during the quarter.
Cowen and Company sold 262 TherapeuticsMD shares in Q4 2019, an estimated $48K.
Cowen and Company first reported a position in TherapeuticsMD in Q3 2019 and held it in 1 quarter.
Cowen and Company's TherapeuticsMD position peaked at $48K in Q3 2019.
168 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2019.

Based on Cowen and Company's 13F filing for Q4 2019, filed 11 Feb 2020.